Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

528
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
528
Proofreading01:31

Proofreading

6.3K
Synthesis of new DNA molecules is carried out by the enzyme DNA polymerase, which adds nucleotides on the daughter strand complementary to the template DNA strand. DNA polymerase has a higher affinity to add the correct base and ensures fidelity during DNA replication. Furthermore,  it exhibits proofreading activity during replication, using an exonuclease domain that cuts off incorrect nucleotides from the nascent DNA strand.
Errors During Replication are Corrected by the DNA Polymerase...
6.3K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

180
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
180
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

16.7K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.7K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

261
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
261
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>TOR2A</i> Variants in Blepharospasm.

Tremor and other hyperkinetic movements (New York, N.Y.)·2023
Same author

Palmaris Brevis Syndrome: A Treatable Pseudodystonia.

Tremor and other hyperkinetic movements (New York, N.Y.)·2021
Same author

Consequences of Cre-mediated deletion of Ciz1 exon 5 in mice.

FEBS letters·2018
Same author

Whole-exome sequencing for variant discovery in blepharospasm.

Molecular genetics & genomic medicine·2018

Related Experiment Video

Updated: Jun 25, 2025

Optogenetic Phase Transition of TDP-43 in Spinal Motor Neurons of Zebrafish Larvae
07:14

Optogenetic Phase Transition of TDP-43 in Spinal Motor Neurons of Zebrafish Larvae

Published on: February 25, 2022

6.0K

Polymerase I as a Target for Treating Neurodegenerative Disorders.

Mark S LeDoux1,2

  • 1Department of Psychology and College of Health Sciences, University of Memphis, Memphis, TN 38152, USA.

Biomedicines
|May 25, 2024
PubMed
Summary
This summary is machine-generated.

Targeting Polymerase I (Pol I) for rRNA synthesis offers a novel therapeutic strategy for neurodegenerative diseases by reducing abnormal protein production. Further research is needed to determine safe and effective inhibition protocols for neurons.

Keywords:
DNAneurodegenerationneuroregressionnucleoluspolymerase Iupstream binding transcription factor (UBTF)

More Related Videos

Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models
13:47

Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models

Published on: March 29, 2019

9.6K
Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis
13:31

Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis

Published on: February 12, 2015

8.8K

Related Experiment Videos

Last Updated: Jun 25, 2025

Optogenetic Phase Transition of TDP-43 in Spinal Motor Neurons of Zebrafish Larvae
07:14

Optogenetic Phase Transition of TDP-43 in Spinal Motor Neurons of Zebrafish Larvae

Published on: February 25, 2022

6.0K
Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models
13:47

Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models

Published on: March 29, 2019

9.6K
Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis
13:31

Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis

Published on: February 12, 2015

8.8K

Area of Science:

  • Molecular Biology
  • Neuroscience
  • Oncology

Background:

  • Polymerase I (Pol I) is central to ribosomal RNA (rRNA) synthesis, a process crucial for protein production.
  • Pol I is an established therapeutic target in cancer treatment.
  • Neurodegenerative diseases share cellular mechanisms with cancer, suggesting Pol I as a potential therapeutic target.

Purpose of the Study:

  • To explore the potential of targeting Pol I or rRNA synthesis for treating neurodegenerative disorders.
  • To investigate the link between Pol I activity, abnormal protein accumulation (e.g., alpha-synuclein, tau), and neuronal death.
  • To evaluate Pol I inhibition as a strategy to reduce protein production and potentially slow aging.

Main Methods:

  • This study is primarily a conceptual review and hypothesis-driven exploration.
  • It analyzes the role of Pol I in protein synthesis and its relevance to neurodegenerative pathologies.
  • It identifies key questions regarding neuronal tolerance and optimal inhibition strategies for Pol I.

Main Results:

  • Cellular accumulation of abnormal proteins like alpha-synuclein and tau is a hallmark of neurodegenerative diseases.
  • Reduced protein production via Pol I inhibition is proposed as a viable therapeutic approach.
  • Abnormalities in Pol I activity may contribute to nuclear stress, DNA damage, and neuronal death.

Conclusions:

  • Targeting Pol I represents a promising, yet largely unexplored, therapeutic avenue for neurodegenerative diseases.
  • Critical questions remain regarding the safe and effective application of Pol I inhibition in neuronal contexts.
  • Further research is essential to determine optimal inhibition parameters (dosage, duration) and to understand cellular compensatory mechanisms.